---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-005749"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:17:43.324826+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zomedica Q1 revenue $6.5M (+4% YoY), net loss $63.8M on $55.8M impairment

## Summary
- Revenue $6.5M (+4% YoY); gross margin 68% vs 66% in Q1 2024.
- Net loss $63.8M includes $55.8M non-cash impairment from share price decline.
- Adjusted EBITDA loss $5.7M vs $5.3M in Q1 2024; cash & securities $64.6M.
- Consumables revenue up 13% to $4.5M; Diagnostics down 25% to $0.6M.
- Shares outstanding 979.9M; liquidity down from $71.4M at Dec 31, 2024.

## SEC filing metadata
- accession: 0001654954-25-005749
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495425005749/0001654954-25-005749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495425005749/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-005749
- JSON: https://secwatch.observer/filing/0001654954-25-005749.json
- Plain text: https://secwatch.observer/filing/0001654954-25-005749.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.